Bimaprost Eye Drops
Bimaprost is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension.
Dosage & Administration
The recommended dosage is one drop in the affected eye(s) once daily in the evening. Bimaprost should not be administered more than once daily since it has been shown that more frequent administration of prostaglandin analogs may decrease the intraocular pressure lowering effect.
Reduction of the intraocular pressure starts approximately 4 hours after the first administration with maximum effect reached within approximately 8 to 12 hours.
Bimaprost may be used concomitantly with other topical ophthalmic drug products to lower intraocular pressure. If more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes apart.
Pigmentation: Pigmentation of the iris, periorbital tissue (eyelid) and eyelashes can occur. Iris pigmentation is likely to be permanent. Eyelash Changes: Gradual change to eyelashes including increased length, thickness and number of lashes. Usually reversible.
Pregnancy: Category C
There are no adequate and well-controlled studies of Bimaprost administration in pregnant women. Because animal reproductive studies are not always predictive of human response. Bimaprost should be administered during pregnancy only if the potential benefit justifies the potential risk to the fetus.
It is not known whether Bimaprost is excreted in human milk, although in animal studies, bimatoprost has been shown to be excreted in breast milk. Because many drugs are excreted in human milk, caution should be exercised when Bimaprost is administered to a nursing woman.
Use in pediatric patients below the age of 16 years is not recommended because of potential safety concerns related to increased pigmentation following long-term chronic use.
No overall clinical differences in safety or effectiveness have been observed between elderly and other adult patients.